Polycythemia Vera

Drugs for Myelofibrosis/Polycythemia Vera

Here are the drugs and financial support services available to patients receiving treatment for Myelofibrosis/Polycythemia Vera.

Inrebic (fedratinib) Capsules

Drug company: Celgene

Inrebic is a kinase inhibitor oral medication used for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis, a type of chronic blood cancer.

Celgene Patient Support offers 3 financial assistance programs for patients who have been prescribed Inrebic:

Celgene Commercial Co-pay Program

This program reduces the cost of Inrebic to $25 for eligible patients who have commercial (private) insurance, with a maximum benefit of $10,000 per year.

Celgene Patient Assistance Program

Patients with no insurance or with not enough insurance to cover their medication, who meet certain financial criteria, may be able to receive Inrebic for free.

Celgene Patient Support

This program connects patients who have public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Jakafi (ruxolitinib)

Drug company: Incyte

Jakafi is a kinase inhibitor used for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis, as well as for patients with polycythemia vera who cannot use or cannot benefit from treatment with hydroxyurea. Myelofibrosis, polycythemia vera, and essential thrombocythemia are 3 types of myeloproliferative neoplasms (or MPNs), which are rare and chronic blood cancers and have only a few approved treatments.

Incyte offers 3 financial assistance programs for patients who are using Jakafi:

IncyteCARES Copay/Coinsurance Assistance Program

Patients with commercial or private insurance who are eligible to receive Jakafi pay as little as $0 monthly. The amount of savings will not exceed $11,977 monthly and $25,000 annually.

To enroll in this program, patients must call IncyteCARES (855-452-5234) to determine eligibility; a membership number is provided immediately and a copay/co-insurance card is activated for eligible patients. To receive copay assistance, patients must contact the specialty pharmacy and provide copay information. Eligible patients experiencing an insurance coverage delay can receive a free supply of Jakafi.

IncyteCARES Patient Assistance Program

Patients without prescription drug coverage for Jakafi, or those whose insurance has denied claims, may be eligible to receive the drug free of charge through this program. To enroll in this program, patients must reside in the United States or Puerto Rico, have an annual household income of less than $125,000 or 600% of the federal poverty level, whichever is greater, and have a valid prescription for an FDA-approved indication.

Patients and their providers must complete the enrollment form and fax it to 855-525-7207 or mail it directly to the address listed on the form.

IncyteCARES Temporary Access Program

Eligible patients who experience a delay in insurance coverage may be able to receive a free 30-day supply of Jakafi. Patients must have private or commercial coverage to qualify for this program.

Table. Drugs Prescribed for Myelofibrosis or Polycythemia Vera

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.